Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
LUND, Sweden, Feb. 18, 2016 --
Laquinimod
- In April, it was announced that the first patient was enrolled to ARPEGGIO, which is evaluating laquinimod's potential for treatment of primary progressive multiple sclerosis (PPMS)
- In June, it was announced that the company was to focus its operations on the laquinimod projects and adjust the organization accordingly
- In June, it was announced that the Phase 3 laquinimod study CONCERTO was fully enrolled
- In October, Teva presented data concerning laquinimod for the treatment of multiple sclerosis at the ECTRIMS congress
- The high dose group in the clinical studies CONCERTO, ARPEGGIO and LEGATO has been discontinued due to cardiovascular events
- The study results from both the pivotal clinical Phase 3 study CONCERTO in relapsing remitting multiple sclerosis (RRMS) and the Phase 2 study ARPEGGIO, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the first half of 2017
Tasquinimod
- In April, it was announced that Active Biotech and Ipsen were to discontinue development of tasquinimod for the treatment of prostate cancer
- The final results from the 10TASQ10 study were presented in September 2015 at the ECC conference and demonstrated that while the primary endpoint was reached and tasquinimod treatment resulted in a prolonged radiographic progression-free survival (rPFS), 7.0 vs. 4.4 months, the positive effect on rPFS did not translate into an improved OS
ANYARA, Paquinimod (57-57) and ISI
- Out-licensing activities are continuing
Financial summary
| MSEK | Oct - Dec | Jan. - Dec. | ||||
| 2015 | 2014 | 2015 | 2014 | |||
| Net sales | 5.0 | 2.9 | 16.3 | 10.4 | ||
| Operating loss | -28.2 | -55.6 | -177.9 | -228.5 | ||
| Loss for the period | -40.8 | -57.0 | -193.5 | -231.5 | ||
| Loss per share, before and after dilution (SEK) | -0.45 | -0.73 | -2.15 | -3.02 | ||
| Cash and cash equivalents | 103.6 | 328.5 | ||||
For further information, please contact:
Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00
The report is also available at www.activebiotech.com.
Active Biotech AB Year-end report January - December 2015 http://hugin.info/1002/R/1986986/729147.pdf
HUG#1986986
